|Bid||41.50 x 1800|
|Ask||41.63 x 900|
|Day's Range||40.57 - 43.06|
|52 Week Range||34.88 - 277.80|
|Beta (5Y Monthly)||1.51|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 02, 2022 - Nov 07, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||124.60|
Subscribe to Yahoo Finance Plus to view Fair Value for NVAX
Commission-free trading platform Robinhood Markets grew in prominence helping newer investors participate in what remains one of the best ways to accumulate wealth over time. One example is Ocugen (NASDAQ: OCGN). Can Ocugen succeed in the COVID-19 vaccine market?
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that partner, SK bioscience, has received a Post Approval Change Application approval from the Korean Ministry of Food and Drug Safety (KMFDS) for Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-
A hugely disappointing quarter and new bear takes on the company by analysts made for a very bad set of trading days.